PDF(Pubmed)
Abstract：
Perampanel (PER) is an antiseizure medication (ASM) with a unique mechanism of action, which was approved in Japan for use in combination therapy in 2016 and as a monotherapy in 2020. It has exerted antitumor effects against several types of tumors in vitro. However, the efficacy of PER monotherapy for seizure control is not well-established in patients with brain tumor. In the present study, 25 patients with brain tumor treated using PER monotherapy at our institution were analyzed and compared with 45 patients treated using the most commonly prescribed ASM, levetiracetam (LEV). The PER group was younger and had a higher frequency of glioma cases. During drug administration, seizures were observed in two patients from the PER group (8.0%) and five patients from the LEV group (11.1%); however, the difference was not significant. The incidence of adverse effects did not significantly differ between the groups (12.0 and 2.2%, respectively). In the PER group, mild liver dysfunction was observed in two patients and drug rash in one. In the LEV group, a drug-induced rash was observed in one patient. PER monotherapy may be safe and effective for seizure treatment or prophylaxis in patients with brain tumor. Further large-scale clinical studies are warranted.
摘要：
Perampanel（PER）是一种具有独特作用机制的抗癫痫药物（ASM），2016年在日本批准用于联合治疗，2020年作为单一治疗。它在体外对几种类型的肿瘤发挥了抗肿瘤作用。然而,在脑肿瘤患者中,PER单药治疗控制癫痫发作的疗效尚不明确.在本研究中,分析了在我们机构使用PER单一疗法治疗的25例脑肿瘤患者，并与使用最常用处方ASM治疗的45例患者进行了比较。左乙拉西坦（LEV）。PER组较年轻，胶质瘤病例发生频率较高。在药物管理期间，在PER组的2例患者(8.0%)和LEV组的5例患者(11.1%)中观察到癫痫发作;然而,差异不显著。两组之间的不良反应发生率没有显着差异（12.0％和2.2％，分别)。在PER组中，2例患者出现轻度肝功能障碍,1例患者出现药疹.在LEV组中,在一名患者中观察到药物诱发的皮疹。PER单一疗法对于脑肿瘤患者的癫痫发作治疗或预防可能是安全有效的。需要进一步的大规模临床研究。
